DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Chronic Lymphocytic Leukemia (CLL)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016" report to their offering.
Chronic Lymphocytic Leukemia - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe.
A key objective of the Chronic Lymphocytic Leukemia Report is to understand the market and pipeline status of the drugs around the Chronic Lymphocytic Leukemia to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline strategies. The Report provides the historical and forecasted sales of the drugs till 2018.
The Chronic Lymphocytic Leukemia Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Chronic Lymphocytic Leukemia.
While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the Global API Manufacturers across the globe covering Drug Master Filings of US, Europe and API Manufacturers in Asia specifically China and India.
Key Topics Covered:
1. Indication Overview
2. Market Drugs Landscape
3. Global API Manufacturers Assessment
4. Phase III Drugs Landscape
5. Drugs Market Data and Forecasted Sales Figure-2018
6. Marketed Drugs for Chronic Lymphocytic Leukemia
7. Phase III Drugs for Chronic Lymphocytic Leukemia
8. Discontinued Drugs for Chronic Lymphocytic Leukemia
For more information visit http://www.researchandmarkets.com/research/sc3mmc/chronic